Business · 07/10/2020Updated: 10/17/2026 · 1 min read
FDA Announces Fee Rate for Rare Pediatric Disease Priority Review Voucher for FY 2021
Summary
The US Food and Drug Administration (FDA) has set the fee rate for using a rare pediatric disease priority review voucher for fiscal year 2021, based on the average cost of reviewing human drug applications in the previous year.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →